Protexo is eligible for patients with the following clinical profile:

Poorly controlled (ACT*<18) atopic asthma despite high treatment intensity (GINA* 4)

Sensitized to at least one perennial allergen

*ACT= Asthma Control Test
*GINA= Global Initiative for Asthma